The HINT2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product features targeted disruption of the HINT2 gene, generating a heterogeneous pool of cells with loss-of-function mutations. By abolishing HINT2 expression, the model enables systematic investigation of its tumor-suppressive activities and regulatory role in mitochondrial apoptosis. As a polyclonal population, it preserves natural genetic variation while providing a robust experimental system for functional genomics and drug response studies in lung cancer biology.
The parental A-549 cell line was originally isolated from the lung carcinoma tissue of a 58-year-old Caucasian male in 1972. These cells exhibit a hypotriploid karyotype and grow as an adherent monolayer with epithelial morphology. A-549 cells are widely regarded as an in vitro model of type II alveolar epithelial cells, recapitulating key features of pulmonary adenocarcinoma. Their well-characterized signaling networks and reproducible growth kinetics make them a preferred host for gene-editing studies, particularly those addressing apoptosis resistance, oncogenic transformation, and mitochondrial dysfunction in lung cancer.
HINT2 encodes a mitochondrial histidine triad nucleotide-binding protein that functions as a hydrolase and tumor suppressor. The protein localizes to the inner mitochondrial membrane and sensitizes cells to intrinsic apoptosis. HINT2 expression is regulated by p53 and AMPK, and its activity is influenced by metabolic stress and reactive oxygen species. Once activated, HINT2 promotes BAX oligomerization, cytochrome c release into the cytosol, and subsequent formation of the APAF1-caspase-9 apoptosome. This cascade activates executioner caspases-3 and PARP1 cleavage, facilitating orderly cell death. HINT2 physically interacts with HINT1, components of the mitochondrial contact site and cristae organizing system (MICOS) complex, and adenine nucleotide translocase, thereby coupling metabolic cues to the apoptotic machinery.
In the A-549 background, HINT2 knockout disrupts p53-mediated BAX activation and attenuates cytochrome c mobilization from mitochondria, impairing the intrinsic apoptosis pathway. This loss of pro-apoptotic signaling can confer resistance to genotoxic stress and may enhance tumorigenic phenotypes, making the model particularly relevant for studying apoptosis evasion mechanisms in lung adenocarcinoma. The polyclonal nature of the knockout population mirrors tumor heterogeneity and allows assessment of variable HINT2 dependency across individual cells, providing insights into apoptosis signaling thresholds and mitochondrial health in cancer.
This HINT2 knockout model is suitable for a diverse array of research applications, including mechanistic studies of mitochondrial apoptosis, metabolic reprogramming, and drug sensitivity profiling. Typical experimental workflows incorporate Western blotting and RT-qPCR for expression analysis, Annexin V/PI staining and JC-1 assays for apoptosis and mitochondrial membrane potential quantification, and MTT/resazurin viability assays under chemotherapeutic challenge. Migration phenotypes can be evaluated using transwell assays, and cytochrome c release can be monitored by ELISA. These tools collectively support rigorous dissection of p53-AMPK-HINT2 signaling axes and the identification of novel therapeutic vulnerabilities. For further technical details or customized support, contact Ascent Research.
